These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 11012191

  • 1. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W, Menchaca D.
    Stem Cells; 1998; 16 Suppl 2():193-8. PubMed ID: 11012191
    [Abstract] [Full Text] [Related]

  • 2. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL.
    Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
    [Abstract] [Full Text] [Related]

  • 3. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.
    Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

  • 5. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
    Ide Y, Harada K, Imai A, Yanagida M.
    Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
    [Abstract] [Full Text] [Related]

  • 6. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K, Akahori H, Shibuya K, Nitta Y, Ida M, Kusaka M, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
    [Abstract] [Full Text] [Related]

  • 7. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [Abstract] [Full Text] [Related]

  • 8. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H, Shibuya K, Ozai M, Ida M, Kabaya K, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [Abstract] [Full Text] [Related]

  • 9. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H.
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [Abstract] [Full Text] [Related]

  • 10. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG.
    Blood; 1997 May 01; 89(9):3118-28. PubMed ID: 9129014
    [Abstract] [Full Text] [Related]

  • 11. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM, MacVittie TJ, Roskos L, Stead RB.
    Stem Cells; 2003 May 01; 21(1):79-89. PubMed ID: 12529554
    [Abstract] [Full Text] [Related]

  • 12. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
    Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L.
    N Engl J Med; 1997 Feb 06; 336(6):404-9. PubMed ID: 9010146
    [Abstract] [Full Text] [Related]

  • 13. Thrombopoietin: biology and clinical potentials.
    Miyazaki H, Kato T.
    Int J Hematol; 1999 Dec 06; 70(4):216-25. PubMed ID: 10643146
    [Abstract] [Full Text] [Related]

  • 14. The use of PEG-rhuMGDF in platelet apheresis.
    Kuter DJ.
    Stem Cells; 1998 Dec 06; 16 Suppl 2():231-42. PubMed ID: 11012195
    [Abstract] [Full Text] [Related]

  • 15. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG.
    Lancet; 1996 Nov 09; 348(9037):1279-81. PubMed ID: 8909381
    [Abstract] [Full Text] [Related]

  • 16. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D, Fairchild D, Schindler-Horvat J, Munyakazi L, Neumann TA.
    Toxicol Sci; 1998 Sep 09; 45(1):77-87. PubMed ID: 9848114
    [Abstract] [Full Text] [Related]

  • 17. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
    Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS.
    Br J Haematol; 2006 Dec 09; 135(5):642-50. PubMed ID: 17054431
    [Abstract] [Full Text] [Related]

  • 18. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G, Hartley C, McElroy P, McCrea C, Kerzic P, McNiece I.
    Stem Cells; 1997 Dec 09; 15(1):43-9. PubMed ID: 9007221
    [Abstract] [Full Text] [Related]

  • 19. Effect of PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on growth and differentiation of the HEL cell line.
    Catani L, Gugliotta L, Motta M, Tazzari P, Baravelli S, Tura S.
    Haematologica; 1998 May 09; 83(5):385-91. PubMed ID: 9658720
    [Abstract] [Full Text] [Related]

  • 20. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.
    Blood; 1996 Jul 15; 88(2):511-21. PubMed ID: 8695799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.